Add-on synthetic progestins for testosterone suppression in feminizing HRT
- Study: Spironolactone with medroxyprogesterone acetate suppresses testosterone in trans women more effectively than spironolactone alone (September 2019)
- Spironolactone can be ineffective as an antiandrogen for many trans women (November 2019)
Cyproterone acetate (CPA) dosage and meningioma brain tumor risk
- Cyproterone acetate and meningioma risk in trans women (March 2018)
- Update on case reports: Cyproterone acetate and meningioma in trans women (November 2018)
- Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects (August 2020)
- Study of entire French population offers further data on cyproterone acetate and meningioma risk (February 2021)
Use of synthetic progestins (cyproterone acetate, medroxyprogesterone acetate, norethindrone, lynestrenol) as part of puberty blockers for trans adolescents
Progesterone as part of a feminizing HRT regimen, progesterone levels, and lack of correlation with estrogen or testosterone levels
- Put it under your tongue? Typical hormone levels for trans women on HRT, and differing effects of oral and parenteral estradiol (January 2021)
Experiences of negative mood and emotional effects from progesterone and synthetic progestins
- Darker shades of pink: Having depression when you’re transgender (March 2014)
- Progesterone may not be only beneficial or ineffective for trans women – for some, it can be actively harmful (January 2020)
Unclear impact of progesterone or progestins on breast growth
- Studies on trans women’s breast development (March 2017)
- Three-year study examines trans women’s breast development from feminizing HRT (November 2020)
Progesterone in inducted lactation for trans women
